UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed No Clinically Relevant Benefit For Patients
Links shared publicly online about this topic.
- 1,927total visits
UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed No Clinically Relevant Benefit For Patients
UCB and Biogen Idec announced today the discontinuation of the Phase II clinical trial of CDP323 for the treatment of relapsing multiple sclerosis (MS). Preliminary interim efficacy analysis show
View full resource at medicalnewstoday.com
Tags: Multiple Sclerosis, Clinical Trial, UCB, Biogen Idec
Most Recently Shared on July 2, 2009 at 3:09 pm By:
MedNewsToday: UCB And Biogen Idec Discontinue Phase II Clinical Trial Of CDP323 - Analysis Showed N.. http://tinyurl.com/ldcur7
Advertisement
